[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517366":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Harbin Medical University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Polyvascular disease",null,[12],"Diagnostic Test: Magnetic Resonance Angiography, Ocular OCTA, CT Angiography",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Magnetic Resonance Angiography, Ocular OCTA, CT Angiography","Magnetic Resonance Angiography of intracranial artery, carotid artery, renal artery and lower extremity artery, CT angiography of coronary artery or intracranial artery",[9],[20],{"name":21,"affiliation":22,"role":23},"Haibo Jia, MD. Ph.D","The Second Affiliated Hospital of Harbin Medical University","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Minghao Liu, MD.","CONTACT","+8613764166251","baiyuedao@alumni.sjtu.edu.cn",[31],{"facility":22,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Harbin","Heilongjiang","150000","China","CN",{"type":39,"coordinates":40},"Point",[41,42],126.65,45.75,{"lat":42,"lon":41},[45],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":23,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Yu Bo","Director","100517366","an-imaging-study-of-polyvascular-disease-100517366",false,"NCT06016608","An Imaging Study of Polyvascular Disease","Early Screen, Systematic Evaluation and Risk Warning of Polyvascular Disease Based on Multi-modality Imaging","Inclusion Criteria:\n\nTask 1:\n\n1. Patients with coronary artery disease (≥50% stenosis in any coronary artery on coronary angiography)\n2. Age ≥18 years old\n3. Proposed OCT-IVUS integrated imaging system\n4. able to provide written informed consent prior to the start of any procedures related to the study.\n\nTask 2:\n\n1. patients with coronary artery disease (coronary angiography reveals ≥50% degree of stenosis in any coronary artery) and patients with stroke or TIA (confirmed by a neurologist)\n2. Age ≥ 18 years\n3. able to provide written informed consent prior to the start of any procedures related to the study.\n\nExclusion Criteria:\n\nTask 1:\n\n1. severely tortuous\u002Fcalcified coronary arteries with anticipated difficulty in completing the OCT-IVUS integrated imaging system\n2. uncontrolled congestive heart failure or acute left heart failure;plan\n3. claustrophobia;\n4. left main stem occlusion;\n5. proposed coronary artery bypass grafting (CABG);\n6. uncontrolled severe ventricular arrhythmia;\n7. active bleeding or severe bleeding tendency;\n8. acute stroke;\n9. patients with hemodynamic instability or unstable cardiac electrical activity (including shock) ;\n10. severe renal insufficiency and\u002For anuria, except in cases where dialysis treatment has been planned;\n11. contraindications to the application of contrast media;\n12. patients who are severely uncooperative due to psychiatric or serious systemic illness;\n13. Patients who, in the opinion of the investigator, are unsuitable for participation in the study.\n\nTask 2:\n\n1. patients who are unable to comply with the follow-up schedule;\n2. uncontrolled congestive heart failure or acute left heart failure;\n3. patients with a life expectancy of less than 6 months;\n4. left main stem occlusion;\n5. proposed coronary artery bypass grafting (CABG);\n6. uncontrolled severe ventricular arrhythmia;\n7. active bleeding or severe bleeding tendency;\n8. patients with hemodynamic instability or unstable cardiac electrical activity (including shock) ;\n9. severe renal insufficiency and\u002For anuria, except in cases where dialysis treatment has been planned;\n10. contraindications to the application of contrast media;\n11. patients who are severely uncooperative due to psychiatric or serious systemic illness;\n12. patients who, in the opinion of the investigator, are not suitable for participation in the study.","ALL","18 Years",{"count":59,"type":60},1100,"ESTIMATED","OBSERVATIONAL","1. Establish a multimodality imaging database for PVD, improve the one-stop screening process for early PVD based on artificial intelligence, build a full-cycle control information platform, and promote the construction and standardization of a multidisciplinary co-morbidity and co-management diagnosis and treatment model.\n2. Based on non-invasive, zero-contrast ocular OCTA combined with one-stop CTA imaging of the heart and brain, construct an integrated \"eye-heart-brain\" early warning model for PVD, and explore a potential non-invasive and convenient early warning system for PVD.\n3. Based on the multi-omics, investigate EVs-mediated intercellular communication network, elucidate the roles and regulatory mechanisms of EVs in the development of PVD, search for potential targets for intervention, and construct an artificial intelligence-based \"pan-vascular score\" risk assessment system based on the combination of multi-modality imaging and multi-omics biomarkers.",[64],"Polyvascular Disease","2024-12-22",{"date":67,"type":68},"2024-12-27","ACTUAL",{"date":70,"type":68},"2023-10-18",{"date":72,"type":60},"2025-12-31",{"name":5,"class":6},1]